published_or_final_version / Anatomy / Doctoral / Doctor of Philosophy

Trophic factors have shown great promise in their potential to treat neurological disease. In particular, glial cell line-derived neurotrophic factor (GDNF) has been identified as a potent neurotrophic factor for midbrain dopamine (DA) neurons in the substantia nigra (SN), which lose function in Parkinson’s disease (PD). GDNF progressed to phase II clinical trials, which did not meet proposed endpoints. The large size and binding characteristics of GDNF have been suspected to contribute to some of the shortcomings of GDNF related to delivery to target brain regions. Smaller peptides derived from GDNF (Dopamine-Neuron Stimulating Peptides – DNSPs) have been recently investigated and appear to demonstrate trophic-like effects comparable to GDNF. In the described studies, a time course study was conducted to determine in vivo DA-release characteristics 1-, 2- and 4- weeks after peptide treatment. These studies determined the effects on DA terminals within striatal sub-regions using microelectrodes. A heterogeneous effect on striatal sub-regions was apparent with the maximum effect in the dorsal striatum – corresponding to terminals originating from the SN. Dysregulation of GDNF or GDNF signaling is believed to contribute to motor dysfunction in aging and PD. Thus, it is hypothesized that GDNF is necessary for the maintenance and function of neurons. To extend this line of investigation, in vivo functional measures (DA-release and -uptake) and behavioral and cellular alterations were investigated in a transgenic mouse model (Gdnf+/-) with reduced GDNF protein levels. The described studies determined that both DA-uptake and -release properties were altered in middle-aged Gdnf+/- mice with only modest reductions in DA neurochemical levels. GDNF levels in Gdnf+/- mice were restored to levels comparable to wild-type (WT) counterparts by treatment with GDNF. GDNF protein supplementation led to enhanced motor behavior and increased markers for DA neurons in the SN of Gdnf+/- mice. Gdnf+/- mice appeared to show a heightened sensitivity to GDNF treatment compared to WT counterparts. Overall, this body of work examines novel synthetic peptides with potential to enhance DA-neuron function and expands upon the current understanding of GDNF’s role in the nigrostriatal pathway.

Major depressive disorder (MDD) and bipolar disorder (BD) are psychiatric diseases that affect behavior and impair cognition. A gene important to these disorders is the brain derived neurotrophic factor (BDNF) which is involved in processes controlling neuroplasticity. Previous studies have suggested that BDNF expression levels have to be finely regulated for normal mental health and cognition. This study therefore aimed to identify cis-regulatory elements that regulate BDNF promoter IV (BP4), which plays a role in mood and cognition, and investigated how polymorphisms in these cis-regulatory elements might alter BP4 activity contributing to MDD and BD. BP4-LacZ transgenic mice and primary neuron cultures were used to show that BP4 was active in the hippocampus, cortex and amygdala and responded to PKC, KCl and Wnt signaling activation. Using comparative genomics, two highly conserved regions were identified, BE5.1 and BE5.2, which contain the rs10767664 and rs12273363 polymorphisms respectively. Reporter gene assays in primary cultures derived from these brain structures showed that BE5.1 and BE5.2 were responsible for “filtering” or “gating” the effects of different combination of activated signal transduction pathways on BP4. Thus, BE5.1 increased BP4 response to forskolin in cortical cultures while abolishing BP4 response to PMA in hippocampal cultures. Similarly, BE5.2 permitted BP4 response to KCl and combined forskolin and PMA treatment, but not individual forskolin and PMA treatment nor LiCl in cortical cultures. Significantly, the minor allele of rs12273363, which has been associated with MDD and BD susceptibility, acted as a more potent repressor of BP4 response to neuron depolarization by KCl and PKA/PKC activation in different primary cultures. The possible relevance of these findings to the role of altered BDNF expression in MDD and BD are discussed.

Stress is a major risk factor for substance abuse. Intermittent social defeat stress increases drug self-administration (SA) and elevates brain-derived neurotrophic factor (BDNF) expression in the ventral tegmental area (VTA) in rats. Intra-VTA BDNF overexpression enhances social defeat stress-induced cross-sensitization to psychostimulants and induces nucleus accumbens (NAc) ΔFosB expression. Therefore, increased VTA BDNF may mimic or augment the development of drug abuse-related behavior following social stress. To test this hypothesis, adeno-associated virus (AAV) was infused into the VTA to overexpress either GFP alone (control) or GFP + BDNF. Rats were then either handled or exposed to intermittent social defeat stress before beginning cocaine SA training. The SA acquisition and maintenance phases were followed by testing on a progressive ratio (PR) schedule of cocaine reinforcement, and then during a 12-h access "binge" cocaine SA session. BDNF and ΔFosB were quantified postmortem in regions of the mesocorticolimbic circuitry using immunohistochemistry. Social defeat stress increased cocaine intake on a PR schedule, regardless of virus treatment. While stress alone increased intake during the 12-h binge session, socially-defeated rats that received VTA BDNF overexpression exhibited even greater cocaine intake compared to the GFP-stressed group. However, VTA BDNF overexpression alone did not alter binge intake. BDNF expression in the VTA was also positively correlated with total cocaine intake during binge session. VTA BDNF overexpression increased ΔFosB expression in the NAc, but not in the dorsal striatum. Here we demonstrate that VTA BDNF overexpression increases long-access cocaine intake, but only under stressful conditions. Therefore, enhanced VTA-BDNF expression may be a facilitator for stress-induced increases in drug abuse-related behavior specifically under conditions that capture compulsive-like drug intake.

Schwermut, Einsamkeit, Desinteresse: 2-7% der Weltbevölkerung werden von diesen Gefühlen bestimmt, sie sind an einer Depression erkrankt. In Deutschland leiden aktuell bis zu 4 Mio. Menschen an einer Depression. Zwei Drittel diese Kollektivs befinden sich in hausärztlicher Behandlung, aber nur etwa die Hälfte von diesen Patienten wird korrekt diagnostiziert und behandelt. Die Gründe hierfür sind auf der einen Seite die schwierige Diagnosefindung, auf der anderen die bisher nicht vollständig geklärte Ätiologie und die komplexen Wirkmechanismen der medikamentösen antidepressiven Therapieoptionen. Die Entstehung einer depressiven Episode ist multifaktoriell bedingt, wobei insbesondere genetischen Faktoren in der Pathogenese depressiver Erkrankungen eine wichtige Rolle zugeordnet wird. Neurobiologische Untersuchungen der molekularen und biochemischen Hintergründe von depressiven Episoden befassen sich zurzeit insbesondere mit drei Hypothesen: Diese sind die Neurotransmitter-Dysbalance-Hypothese (Monoaminhypothese), die Stressachsen-Hypothese (Hypothalamus-Hypophysen-Achse) und die Neurotrophin-Hypothese. Die Stressachsen-Hypothese befasst sich in diesem Zusammenhang mit der Aktivität des Hypothalamus-Hypophysen-Systems, die bei depressiv erkrankten Patienten dysreguliert ist und mit einer erhöhten Kortisolsekretion einhergeht. Die Monoaminhypothese der Depression postuliert eine Dysfunktion serotonerger, noradrenerger und dopaminerger Systeme. Die Neurotrophinhypothese bezieht sich auf das Second Messenger-System des durch Antidepressiva aktivierten cyclischen Adenosin-Monophosphat (cAMP) Signalwegs. Cyclisches Adenosin-Monophosphat aktiviert die cAMP-abhängige Proteinkinase (PKA), die wiederum den Transkriptionsfaktor cAMP response element binding protein (CREB) phosphoryliert und ihn somit stimuliert. Aktiviertes CREB verstärkt die Transkription zahlreicher Zielgene, inklusive die des brain-derived neurotrophic factor (BDNF), welcher unter anderem als Regulator von Neurotransmittern dient und Überleben, Differenzierung und Plastizität von Neuronen beeinflusst. Astrozyten gehören zur Gruppe der Makrogliazellen im zentralen Nervensystem (ZNS) und sind die größte Population der Gliazellen. Sie sind für die Kaliumhomöostase und ebenso für die Regulation der synaptischen Transmission und der neurovaskulären Koppelung zuständig. Des Weiteren scheinen Astrozyten eine wichtige Rolle für die Bildung glialer Narben, die Induktion der Blut-Hirn-Schranke und auch für das neuronale Überleben zu spielen. Bei der Analyse der Wirkmechanismen medikamentöser antidepressiver Therapien ist in der letzten Zeit die Rolle der Astrozyten in den Vordergrund gerückt, um deren Beitrag zu antidepressiven Therapien zu untersuchen. Das Ziel der vorliegenden Arbeit war zu untersuchen, ob in Astrozyten der Serotonin-Transporter (5-HT-Transporter, 5-HTT), der Brain-derived neurotrophic factor (BDNF), der Dopamin-Transporter oder die Stickstoffmonoxyd-Synthase III (endotheliale Stickstoffmonoxid-Synthase, eNOS) gebildet werden und falls ja, ob sich deren Expression durch Applikation von Antidepressiva ändert. Die aus Rattenhirnen gewonnenen Astrozytenkulturen wurden hierfür entweder mit dem trizyklischen Antidepressivum Imipramin, dem selektiven Serotoninrückaufnahmeinhibitor Escitalopram oder zur Kontrolle mit Kochsalzlösung inkubiert. Nachdem die entsprechende mRNA aus den behandelten Astrozytenkulturen extrahiert wurde, ist sie in cDNA translatiert und mit Hilfe der quantitativen Real-Time PCR quantifiziert worden. Durch Vergleich der Expression des zu untersuchenden Gens mit der Expression der Housekeeping-Gene 18s-rRNA, Glycerinaldehyddehydrogenase (GAPDH) und Acidic ribosomal phosphoprotein (ARP) wurden Ungenauigkeiten bei der cDNA-Synthese ausgeglichen und die Daten normalisiert. Die rechnerische Auswertung der quantitativen Real-Time PCR erfolgte unter Verwendung der Ct-Werte unter Zuhilfenahme der geNORM Software. Die Ergebnisse zeigen eine signifikant erhöhte BDNF-Expression nach Imipramingabe. Hierbei zeigen bei den getrennten Untersuchungen der jeweiligen mRNA Chargen die mit 100µM Imipramin behandelten Astrozytenkulturen stärker signifikante Ergebnisse, als die mit 50µM Imipramin behandelten Astrozytenkulturen. Werden alle Proben, die mit der jeweiligen Imipraminkonzentration 4 Stunden inkubiert wurden, zusammen analysiert und mit den jeweiligen Kontrollen verglichen, zeigt sich sowohl bei der Behandlung mit 50µM Imipramin als auch mit 100µM Imipramin eine signifikante Steigerung der BDNF Expression. Escitalopram stimulierte die BDNF-Expression zwar ebenfalls nominell, jedoch war der Effekt nicht signifikant. Des Weiteren konnte eine deutliche Expression von 5-HTT-mRNA in Astrozytenkulturen nachgewiesen werden. Jedoch hatte keines der Antidepressiva einen signifikanten Effekt auf die 5-HTT-Expression. Es konnten weder in den behandelten, noch in den unbehandelten Astrozytenkulturen DAT oder NOS-III nachgewiesen werden. / Melancholia, loneliness, lack of interest: 2-7% of world population are ruled by these feelings. In Germany, 4 million inhabitants suffer from depression. Two third of this population are under medical treatment, but only half of these patients are diagnosed and medicated correctly. Reasons are difficulties in finding the exact diagnosis on the one hand and the vague aetiology and complex effects of antidepressants on the other. The origin of a depressive episode has multiple reasons, especially genetic components are considered to play an important role. Neurobiological investigations of the molecular and biochemical backgrounds of depressive episodes centre on three hypotheses: The dysbalance hypothesis of neurotransmitters (monoamine hypothesis), the hypothesis of activated hypothalamus-pituitary-adrenal axis and the neurotrophin hypothesis. In this context, the hypothesis of activated hypothalamus-pituitary-adrenal axis deals with the dysregulation and over-stimulation of the hypothalamus-pituitary-adrenal axis and the following elevated cortisol-secretion. The monoamine hypothesis of depressive episodes postulates a dysfunction of serotonergic, noradrenergic and dopaminergic systems. The neurotrophin hypothesis refers to the cyclic adenosine monophosphate (cAMP) second messenger system, activated by antidepressants. Cyclic adenosine monophosphate activates the cAMP dependent protein kinase (PKA) that phosphorylates and consequently stimulates the transcription factor cAMP response element binding protein (CREB). Activated CREB enhances the transcription of numerous genes, including the brain derived neurotrophic factor (BDNF) that is among others regulating neurotransmitters and influences neuronal survival, differentiation and plasticity. Astrocytes are part of the macroglia in central nervous system and form the major population of glial cells. They are considered to be responsible for homeostasis of potassium and the regulation of synaptic transmission and neurovascular linkage. Furthermore, astrocytes take part in forming glial cicatrixes, induction of blood-brain-barrier and neuronal survival. In the course of investigating the effects of antidepressants, the centre of interest has focused on astrocytes and their contribution to antidepressant therapy. The aim of this dissertation was to study, if the serotonin transporter (5-HTT), the brain derived neurotrophic factor (BDNF), the dopamin transporter or the nitric oxide synthase III (eNOS) is synthesised in astrocytes and in case of, if their expression is modulated by antidepressants. The astrocyte cultures, gained from rats’ brains, were incubated with the tricyclic antidepressant imipramine, the selective serotonin reuptake-inhibitor escitalopram or sodium chloride solution. After extracting the corresponding mRNA from the astrocyte cultures, it was translated to cDNA and quantified using the quantitative Real-Time PCR. Comparing the expression of the gene of interest with the expression of the housekeeping genes 18s-rRNA, glyceraldehydes phosphate dehydrogenase (GAPDH) and acidic ribosomal phosphoprotein (ARP), equated inexactness of cDNA synthesis and normalised the acquired data. The mathematical evaluation of the qRT-PCR based on the Ct-figures with the assistance of geNORM software. The results show a significantly elevated BDNF expression after imipramine administration. mRNA batches of astrocyte cultures incubated with 100µM imipramine presented more significant results than mRNA batches of astrocyte cultures incubated with 50µM imipramine. Analysing all samples incubated for four hours with the corresponding concentration of imipramine and compared with the sodium chloride solution controls, a significant elevation of BDNF expression is detected in 50µM imipramine samples as well as in 100µM imipramine samples. Escitalopram stimulates the expression of BDNF nominally without showing significant effects. Furthermore, a clear expression of 5-HTT-mRNA in astrocyte cultures could be detected, but none of the antidepressants induced a significant effect on 5-HTT expression. Neither in medicated nor in control samples DAT or NOS-III were detected.

The purpose of this study was to determine if resistance exercise altered peripheral BDNF concentration. Eighteen trained male subjects were split into two groups performing varied repetition ranges. DUP-HR and DUP-LR groups trained 3x/week for 8 weeks, and were equated for total volume (repetitions X sets X intensity). Plasma BDNF and interleukin-6 (IL-6) levels were measured prior to and immediately following the first exercise session of weeks 1, 2, 4 and 6. Pre-exercise levels were also assessed prior to the second and third sessions of week 1 and 6. Lastly, resting levels were measured before and after training intervention. No group differences (p>0.05) were detected for either biomarker. An acute BDNF elevation (p=0.018) was detected only in the final week of training. IL-6 elevations were detected at all acute measurements (p<0.01). BDNF and IL-6 percentage change correlated significantly (p<0.05) in week-1. No chronic alterations were observed (p>0.05). / Includes bibliography. / Thesis (M.S.)--Florida Atlantic University, 2015 / FAU Electronic Theses and Dissertations Collection

The primary purpose of this study was to investigate the effects of aerobic and resistance training on BDNF and IGF-I expression in a 3xTg-AD mouse model of Alzheimer’s disease. Twenty-four 3xTg-AD mice were randomly assigned to either an aerobic (AT, n=8), resistance (RT, n=8), or control (CNT, n=8) group. Intervention groups underwent 9 weeks of exercise training. Motor behavior and grip strength were measured pre- and post- intervention. Our results showed a significant increase in hippocampal BDNF expression in AT mice after a 9-week intervention. Further, AT mice were found to have higher concentrations of IGF-I, and improved motor behavior when compared to RT and CNT. No significant differences were observed in IGF-I concentration between RT and other groups. RT improved grip strength after nine weeks of training. These findings support the use of AT and RT as a tool to improve comorbidities found in Alzheimer’s disease. / Includes bibliography. / Thesis (M.S.)--Florida Atlantic University, 2018. / FAU Electronic Theses and Dissertations Collection

BDNF is a neurotrophin that enhances neural health and is increased by exercise. PURPOSE: To compare moderate continuous (MCE) and high-intensity interval exercise (HIE) effects on serum BDNF levels, and examine the relationship between BDNF and lactate. METHODS: Seven males completed a VO2peak test and two protocols on separate days, (MCE) 28 min at 60% Workrate max (WRmax) and (HIE) 28 min of intervals at 90%WRmax (10- 1 min intervals separated by 2 min of rest). Serum BDNF and lactate were determined prior, during, and following both protocols. RESULTS: BDNF levels (pg/mL) increased from baseline during HIE and MCE (p<.05). The BDNF response to HIE correlated with lactate for area under the curve (AUC) (r=0.901; P<0.05). CONCLUSION: HIE is an effective alternative to MCE at increasing BDNF. Additionally, lactate may act as a measure of intensity or a mediator of the BDNF response to exercise. / Includes bibliography. / Thesis (M.S.)--Florida Atlantic University, 2014. / FAU Electronic Theses and Dissertations Collection

In this thesis is presented work carried out during the course of the last 42 months. It concerns approaches towards total syntheses of the complanadine alkaloids. The main focus is the development of a model system to establish the viability of the key step in our proposed route to the complanadines. The thesis is divided into five chapters. Chapter 1 is an introduction to the complanadines, their biological activity and accomplished total syntheses to date. A brief introduction to the Diels–Alder reaction and selected examples of its application in the total syntheses of natural products are given. The Kondrat’eva oxazole–olefin hetero-Diels–Alder reaction as a method of pyridine formation is described and its application in the total synthesis of natural products is reviewed. Chapter 2 is the first part of the results and discussion section. It details our retrosynthetic analysis of complanadine A, outlines the corresponding proposed forward synthesis and presents a model system designed and synthesised to test the applicability of the Kondrat’eva oxazole–olefin hetero-Diels–Alder reaction in the context of our proposed total synthesis. Chapter 3 discusses work carried out in approaches to the total synthesis of complanadines and their monomeric subunit, lycodine, by means of the methodology developed in the previous chapter. Chapter 4 is the experimental section, which gives descriptions of the synthetic procedures employed and spectroscopic data for all compounds synthesised, both novel and previously reported, as discussed in Chapter 2 and Chapter 3. Supplementary information such as X-Ray data for synthesised compounds and selected NMR spectra are enclosed in the appendices.

Ependymin (EPN) is a goldfish brain neurotrophic factor (NTF) previously shown to function in a variety of cellular events related to long-term memory formation and neuronal regeneration. Because of these functions, EPN and other NTFs have potential applications for treating neuro-degenerative conditions, including stroke. In previous experiments, our lab in collaboration with Victor Shashoua of Ceremedix Inc (Boston, MA), designed short synthetic peptide CMX-8933 (a proteolytic cleavage product of EPN) and CMX-9236 (an EPN-Calmodulin combination peptide) that mimic the action of full-length EPN. In a rat stroke model, administration of these peptides i.v. significantly lowered brain ischemic volume (Shashoua et al., 2003). Because oxidative stress is one of the primary mediators of cell damage following a stroke, we hypothesized that NTFs, and in particular our therapeutic peptides, may act in part by reducing neuronal oxidative stress. Thus, the purpose of this thesis was to determine whether CMX-8933 and CMX-9236 increase the cellular titers of anti-oxidative enzymes. A hybridization array was used as a“hypothesis generator" to obtain candidates for further analysis. This approach applied to rat primary brain cortical cells treated with CMX-8933 identified superoxide dismutase (SOD) as strongly upregulated. SOD immunoblots on whole cell lysates, and RT-PCR on total cellular RNA, were used to confirm this observation. In time-course and dose-response experiments, treatment of rat primary cortical cultures with either peptide showed an optimal 8.5 fold (N = 5, p < 0.001) increase in SOD protein, while administration of CMX-8933 to murine neuroblastoma cells caused a 6.5 fold (N = 3, p = 0.001) increase in SOD mRNA levels. Previous work in other laboratories indicated that systemic (i.v.) administration of full-length NTFs allows only an inefficient delivery across the blood brain barrier (BBB). We hypothesized that our short synthetic peptides may cross the BBB more efficiently. Immunoblot analysis of brains and hearts excised from mice treated i.v. with various doses of CMX-8933 confirmed the elevated SOD titers (10 fold in brain, and 8 fold in heart, at a 6 mg/kg dose for 5 hr; N = 5, p < 0.001). Furthermore, we hypothesized that conjugation of CMX-8933 to BBB carrier DHA, a natural neuronal membrane fatty acid shown previously to enhance the delivery of dopamine to the brain (Shashoua and Hesse, 1996), might further enhance the NTF therapy. Delivery of DHA-8933 increased SOD expression by 3 fold (N = 4, p < 0.001) relative to non-conjugated CMX-8933. Recently, the use of special incubators that allow the culture of cells under low oxygen conditions (anoxia) has been used as an in vitro model for stroke. When we tested our peptides in this new in vitro model, surprisingly SOD was upregulated 3 fold (N = 3, p = 0.003) in rat primary cortical cells cultured for 24 hr under oxygen deprivation, compared to normoxic conditions. This implies that these rat cultures may have an endogenous cellular system for responding to oxygen stress, a finding worthy of further investigation. Treatment of anoxic cells with CMX-8933 increased SOD levels another 2.8 fold (N = 3, p < 0.001) compared to the levels for anoxia alone (for a total of 8.5 fold relative to normoxic cells). Altogether, the data from this thesis illustrate that small NTF EPN peptide mimetics increase the cellular titers of the mRNA and protein for the anti-oxidative enzyme SOD, which may be an important step in their known therapeutic benefits.